See more : Asahi Group Holdings, Ltd. (ASBRF) Income Statement Analysis – Financial Results
Complete financial analysis of Lipum AB (publ) (LIPUM.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lipum AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- GME Resources Limited (GME.AX) Income Statement Analysis – Financial Results
- Design Capital Limited (1545.HK) Income Statement Analysis – Financial Results
- Nyxio Technologies Corporation (NYXO) Income Statement Analysis – Financial Results
- Confidence Petroleum India Limited (CONFIPET.NS) Income Statement Analysis – Financial Results
- Sinopec Oilfield Service Corporation (1033.HK) Income Statement Analysis – Financial Results
Lipum AB (publ) (LIPUM.ST)
About Lipum AB (publ)
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of pediatric rheumatism and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116. The company was founded in 2010 and is headquartered in Umeå, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 53.00K | 0.00 | 0.00 | 14.80K | 39.06K | 2.72K | 16.05 |
| Cost of Revenue | 0.00 | 11.00K | 0.00 | 31.75M | 18.81M | 4.62K | 2.64K |
| Gross Profit | 53.00K | -11.00K | 0.00 | -31.73M | -18.77M | -1.90K | -2.62K |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | -214,355.37% | -48,064.38% | -70.09% | -16,330.94% |
| Research & Development | 26.00M | 29.82M | 47.96M | 27.87M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 31.61M | 48.69M | 27.89M | 15.41M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 37.17M | 31.61M | 48.69M | 27.89M | 15.41M | 514.80 | 0.30 |
| Other Expenses | -25.87M | 6.20M | 4.78M | -6.82M | -6.06M | 0.00 | 0.00 |
| Operating Expenses | 37.31M | 37.81M | 53.48M | 21.07M | 9.36M | 514.80 | 335.33 |
| Cost & Expenses | 37.31M | 37.81M | 53.48M | 21.07M | 9.36M | 5.13K | 2.97K |
| Interest Income | 76.00 | 9.00K | 61.00K | 40.00K | 33.00 | 0.04 | 0.00 |
| Interest Expense | 0.00 | 169.00K | 150.00K | 39.75K | 33.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 40.00K | 11.00K | 53.48K | 20.28K | 9.32K | 2.42K | 2.28K |
| EBITDA | -37.12M | -37.80M | -52.11M | -21.06M | -9.32M | -0.04 | 0.00 |
| EBITDA Ratio | -70,035.85% | 0.00% | 0.00% | -142,254.36% | -23,851.13% | 0.00% | -0.01% |
| Operating Income | -37.25M | -37.93M | -52.11M | -21.06M | -9.32M | -2.42K | -2.28K |
| Operating Income Ratio | -70,290.57% | 0.00% | 0.00% | -142,254.36% | -23,851.13% | -89.05% | -14,241.02% |
| Total Other Income/Expenses | 76.00K | -160.00K | -150.00K | -40.00K | -33.00 | -44.00 | -2.28M |
| Income Before Tax | -37.18M | -38.09M | -52.26M | -21.10M | -9.32M | -2.42K | -2.28K |
| Income Before Tax Ratio | -70,147.17% | 0.00% | 0.00% | -142,522.89% | -23,851.22% | -89.05% | -14,241.03% |
| Income Tax Expense | 0.00 | 160.00K | 150.00K | 39.75K | 33.00 | -0.04 | 0.00 |
| Net Income | -37.18M | -38.25M | -52.41M | -21.14M | -9.32M | -2.42K | -2.28K |
| Net Income Ratio | -70,147.17% | 0.00% | 0.00% | -142,791.41% | -23,851.30% | -89.05% | -14,241.03% |
| EPS | -4.45 | -6.02 | -12.62 | -9.24 | -1.97 | -1.17 | -1.10 |
| EPS Diluted | -4.45 | -6.02 | -12.62 | -9.24 | -1.97 | -1.17 | -1.10 |
| Weighted Avg Shares Out | 8.35M | 6.35M | 4.15M | 2.29M | 4.74M | 2.08K | 2.08K |
| Weighted Avg Shares Out (Dil) | 8.35M | 6.35M | 4.15M | 2.29M | 4.74M | 2.08K | 2.08K |
Source: https://incomestatements.info
Category: Stock Reports